ClinicalTrials.gov
public full text
Public Domain
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression. This clinical study is based on the assumption that adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sertraline as an antidepressant and inflammatory cytokines in depressive disorders : a systematic review and meta-analysis of randomized double-blind placebo-controlled trials#443711
- Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome#1322099
- Cognitive Behavioral Therapy for Depression: Helping Clients Learn New Skills#1396028
- Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder#1352210
- SSRI Effects on Depression and Immunity in HIV/AIDS#1044325
Record · ID 1454170
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive